Keyword: Samsung BioLogics

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.

AZ and Daiichi reported "impressive" data for DS-8201. J&J and Legend's CAR-T showed promise in multiple myeloma. South Korea jailed Samsung execs.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

Biocon, whose problems at its plant in Bengaluru caused approval delays for a key drug, says the FDA has issued the plant an EIR.

WuXi Biologics expects to have a plant in Europe complete in 2021 as a capacity race plays out among Asia’s rapidly growing biologics CDMOs.

Hansoh and Hengrui chiefs together make one of biopharma's richest families; prosecutors grill top Samsung exec; FDA cites another Aurobindo plant.

Celltrion Chairman Seo Jung-jin says the South Korean company will spend about $33 billion over a decade on its biologics and pharma businesses.

Eisai's stock plummets at AD failure; Keytruda has much upside in China, analysts say; Korea Exchange is dragged into Samsung accounting probe.

Samsung BioLogics has faced scrutiny of a biosimilars joint venture. Now, officials are looking more closely into the company's 2016 public listing.

Takeda's dengue vaccine clears phase 3; Pfizer launches China's first pay-for-performance deal in oncology; Aslan cuts 30% of its workforce.